Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss how antibody-drug conjugates have shifted the clinical management of various breast cancer subtypes.
Back
Contextualizing ADC Integration in Breast Cancer Management
Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, explore the evolving role of antibody-drug conjugates in the treatment of breast cancer.
Contextualizing ADC Integration in Breast Cancer Management
Episodes
All
All
Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss how antibody-drug conjugates are weighed against other treatments in breast cancer care.
Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss emerging data for TROP2-directed antibody-drug conjugates in metastatic triple-negative breast cancer.
Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss how the emergence of antibody-drug conjugates may impact sequencing considerations in triple-negative breast cancer.
Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss the role of antibody-drug conjugates in the management of hormone receptor–positive breast cancer.
Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, discuss how antibody-drug conjugates have altered the HER2-positive breast cancer treatment paradigm.
Neil M. Iyengar, MD, and Kelsey Natsuhara, MD, outline key future directions for antibody-drug conjugate (ADC) development in breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to BH-30643 in EGFR C797S+ NSCLC
2
FDA Grants Fast Track Designation to ETX-19477 in BRCA-Mutated HR+/HER2– Breast Cancer
3
FDA Grants Fast Track Designation to Sapanisertib and Serabelisib Plus Paclitaxel in Advanced Endometrial Cancer
4
Dr Leary on a Neo-Epitope-Based Vaccine With or Without Pembrolizumab in Platinum-Sensitive Recurrent Ovarian Cancer
5